Deciphera Pharmaceuticals Inc [NASDAQ: DCPH] closed the trading session at $25.28.
The stocks have a year to date performance of 56.73 percent and weekly performance of 73.39 percent. The stock has been moved at 148.33 percent over the last six months. The stock has performed 60.71 percent around the most recent 30 days and changed 69.10 percent over the most recent 3-months.
If compared to the average trading volume of 516.13K shares, DCPH reached to a volume of 50719699 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Deciphera Pharmaceuticals Inc [DCPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DCPH shares is $25.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DCPH stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Deciphera Pharmaceuticals Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 20, 2023. The new note on the price target was released on October 30, 2023, representing the official price target for Deciphera Pharmaceuticals Inc stock. Previously, the target price had yet another raise from $14 to $20, while Stifel kept a Buy rating on DCPH stock.
The Average True Range (ATR) for Deciphera Pharmaceuticals Inc is set at 1.35, with the Price to Sales ratio for DCPH stock in the period of the last 12 months amounting to 12.73. The Price to Book ratio for the last quarter was 5.80, with the Price to Cash per share for the same quarter was set at 3.72.
DCPH stock trade performance evaluation
Deciphera Pharmaceuticals Inc [DCPH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 73.39. With this latest performance, DCPH shares gained by 60.71% in over the last four-week period, additionally plugging by 148.33% over the last 6 months – not to mention a rise of 77.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DCPH stock in for the last two-week period is set at 85.98, with the RSI for the last a single of trading hit 90.76, and the three-weeks RSI is set at 81.44 for Deciphera Pharmaceuticals Inc [DCPH]. The present Moving Average for the last 50 days of trading for this stock 15.78, while it was recorded at 16.68 for the last single week of trading, and 14.13 for the last 200 days.
Deciphera Pharmaceuticals Inc [DCPH]: An insightful look at the core fundamentals
Deciphera Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.59 and a Current Ratio set at 3.80.
Earnings per share (EPS) analysis for Deciphera Pharmaceuticals Inc [DCPH] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DCPH. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Deciphera Pharmaceuticals Inc go to 21.00%.
Deciphera Pharmaceuticals Inc [DCPH]: Institutional Ownership
The top three institutional holders of DCPH stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in DCPH stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in DCPH stock with ownership which is approximately 5.8386%.
